Weekly Top News – Psoriasis – May 18, 2020

May 18, 2020

mirikizumab (LY3074828) / Eli Lilly
Mirikizumab: Data from P3 OASIS-1 trial (NCT03482011) for psoriasis in H2 2020 (Eli Lilly, Bank of America Merrill Lynch Global Healthcare Conference 2020) – May 15, 2020

 

ABY-035 / Affibody
Affibody and Inmagene announce strategic partnership to develop ABY-035 – a phase 2 drug candidate with best-in-class potential for auto-immune diseases (Cision) – May 16, 2020 – “Affibody AB (‘Affibody’) and Inmagene Biopharmaceuticals (‘Inmagene’) today announced a strategic partnership to develop and commercialize ABY-035, a bispecific molecule targeting Interleukin-17A (IL-17), for multiple auto-immune diseases. Inmagene will be responsible for commercialization in mainland China, Hong Kong, Taiwan, and Macau (Greater China), and South Korea, as well as development activities in the Asia Pacific region, excluding Japan. Affibody will retain global commercial rights outside of Greater China and South Korea. The partners will work together to enroll patients into global registrational trials to support Biologics License Applications (BLAs) in multiple indications worldwide.”

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (clinicaltrials.gov) – May 12, 2020 – P3; N=964; Active, not recruiting; Sponsor: AbbVie; Recruiting –> Active, not recruiting; Trial primary completion date: Jan 2021 –> Oct 2020

 

EDP1815 / Evelo Biosci
Evelo Biosciences reports first quarter financial results and business highlights (GlobeNewswire) – May 11, 2020 – “Selected enteric capsule formulation of EDP1815 for Phase 2 dose ranging trial in psoriasis; trial initiation now expected in 3Q 2020, with interim data in mid-2021….This study will evaluate three doses of the enteric capsule formulation of EDP1815 versus placebo in approximately 225 individuals with mild to moderate psoriasis. The primary endpoint will be mean reduction in PASI score at 16 weeks….Evelo also announced interim data from cohorts of individuals with either mild to moderate psoriasis…who were treated with the newer, alternate formulation of EDP1815 in the ongoing Phase 1b studies. Meaningful clinical responses were not observed in either cohort. Based on these data, Evelo is discontinuing development of the alternate formulation.”

 

GSK2831781 / GSK
GSK2831781: Proof-of-concept data from P1 trial (NCT03965533) for psoriasis in H2 2020 (Immutep) – May 14, 2020 – NWR Virtual Small Cap Health Conference

 

Stelara (ustekinumab) / J&J
PROUST: A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab (clinicaltrials.gov) – May 14, 2020 – P=N/A; N=221; Completed; Sponsor: Janssen Cilag S.A.S.; Active, not recruiting –> Completed

No Comments

Post a Comment

Comment
Name
Email
Website